Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Research & Development (2018 - 2025)

Historic Research & Development for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to $3.7 million.

  • Serina Therapeutics' Research & Development rose 5118.01% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year increase of 10124.54%. This contributed to the annual value of $7.5 million for FY2024, which is 21323.28% up from last year.
  • Latest data reveals that Serina Therapeutics reported Research & Development of $3.7 million as of Q3 2025, which was up 5118.01% from $3.2 million recorded in Q2 2025.
  • Serina Therapeutics' Research & Development's 5-year high stood at $3.7 million during Q3 2025, with a 5-year trough of $162000.0 in Q3 2022.
  • Its 5-year average for Research & Development is $1.2 million, with a median of $481000.0 in 2021.
  • Its Research & Development has fluctuated over the past 5 years, first plummeted by 7346.44% in 2021, then surged by 33605.77% in 2023.
  • Over the past 5 years, Serina Therapeutics' Research & Development (Quarter) stood at $376000.0 in 2021, then plummeted by 44.68% to $208000.0 in 2022, then skyrocketed by 336.06% to $907000.0 in 2023, then surged by 160.75% to $2.4 million in 2024, then surged by 54.38% to $3.7 million in 2025.
  • Its Research & Development was $3.7 million in Q3 2025, compared to $3.2 million in Q2 2025 and $3.0 million in Q1 2025.